35 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
19 Apr 24
Current report (foreign)
6:12am
dosing with ENTYVIO and refer to neurologist; if confirmed, discontinue ENTYVIO dosing permanently. Liver Injury: There have been reports … of significant liver injury. Live and Oral Vaccines: Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all
6-K
TAK
Takeda Pharmaceutical Co
28 Sep 23
Current report (foreign)
6:17am
, withhold dosing with ENTYVIO and refer to neurologist; if confirmed, discontinue ENTYVIO dosing permanently.
Liver Injury: There have been reports … evidence of significant liver injury.
Live and Oral Vaccines: Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all
6-K
TAK
Takeda Pharmaceutical Co
8 Dec 22
Current report (foreign)
6:46am
injection. It is important that precautions are in place to avoid injury from fainting. A protective immune response with Qdenga may not be elicited
6-K
EX-99.1
5l5v k8j7vd3o572
23 Aug 22
Current report (foreign)
6:13am
S-8
EX-99.1
3k0v0h5
29 Jun 22
Registration of securities for employees
6:13am
6-K
EX-99.1
a5tyofl1slexf
6 Apr 21
Current report (foreign)
6:29am
6-K
EX-99.1
pi97ji2 0vuf
17 Dec 20
Current report (foreign)
6:01am
6-K
EX-99.1
gbwaa
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
6-K
EX-99.1
cdfo14uppvm8avxzarz
21 Nov 19
Current report (foreign)
6:08am
6-K
EX-99.1
wu5zu90oitq1lh d91li
14 Nov 19
Current report (foreign)
6:26am
424B3
61u82ksugadbgc
14 Nov 19
Prospectus supplement
6:10am
F-4/A
e4jgew s95cd
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
F-4
nfshkrobht6u4 a17n
9 Aug 19
Registration of securities (foreign)
6:27am
20-F
disutx4e0d
27 Jun 19
Annual report (foreign)
6:41am
20FR12B/A
EX-10.13
skjr9in
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am